Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
Our enLIGHTEN™ Discovery Platform represents a revolutionary step forward in viral immunotherapy development.
This systematic, data-driven platform combines advanced analytics with human biology to create precisely engineered HSV-based gene constructs.
https://www.candeltx.com/platforms/
Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submission | NASDAQ:CADL
Entering 2025 with strong momentum!
Successes in 2024 include positive P3 data for CAN-2409 in prostate cancer & encouraging survival data in pancreatic cancer & NSCLC. We remain focused on advancing viral immunotherapies to help patients fight cancer.
https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-provides-corporate-update-and-highlights
Candel Therapeutics launched into 2025 with positive phase 3 data in localized prostate cancer, new data readouts coming up, and sufficient cash to create more value by getting to BLA submission. Onwards and upwards!
